Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

vTv Therapeutics Inc

VTVT
Current price
12.93 USD -0.39 USD (-2.93%)
Last closed 13.5 USD
ISIN US9183851057
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 32 843 610 USD
Yield for 12 month -9.20 %
1Y
3Y
5Y
10Y
15Y
VTVT
21.11.2021 - 28.11.2021

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC. Address: 3980 Premier Drive, High Point, NC, United States, 27265

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2 USD

P/E ratio

Dividend Yield

Current Year

+9 000 USD

Last Year

+2 018 000 USD

Current Quarter

Last Quarter

+1 000 000 USD

Current Year

-13 595 000 USD

Last Year

+1 926 000 USD

Current Quarter

-23 000 USD

Last Quarter

+978 000 USD

Key Figures VTVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -22 767 000 USD
Operating Margin TTM -2285.7 %
PE Ratio
Return On Assets TTM -41.48 %
PEG Ratio
Return On Equity TTM -362.13 %
Wall Street Target Price 2 USD
Revenue TTM 1 000 000 USD
Book Value 6.77 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -9 933 000 USD
Earnings per share -6.83 USD
Diluted Eps TTM -6.83 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics VTVT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History VTVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:40
Payout Ratio
Last Split Date 21.11.2023
Dividend Date

Stock Valuation VTVT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.3125
Price Sales TTM 32.8436
Enterprise Value EBITDA -2.1056
Price Book MRQ 1.9935

Financials VTVT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators VTVT

For 52 weeks

7.38 USD 30.99 USD
50 Day MA 14.25 USD
Shares Short Prior Month 31 533
200 Day MA 17.91 USD
Short Ratio 1.69
Shares Short 28 958
Short Percent 3.34 %